



# Abstract Plain Language Summaries at Scientific Congresses



## What are abstract plain language summaries (APLS)?

APLS use simple visuals, plain language and consistent terminology to describe the research presented at scientific congresses, or meetings. Each APLS represents a small piece of the complete body of data available on the drug and disease area today.

*APLS reports represent results of only one study. Researchers must look at the results of many types of studies to understand whether a study drug works, how it works, and whether it is safe to prescribe. The results might be different from the outcome of other studies that researchers have presented in the past. It's important to note that these data are investigational, and the treatments may not be approved in these settings by regulatory agencies.*

### WHO ARE APLS FOR?

APLS can help research findings be accessible and understandable to anyone seeking this information. Audiences may include but are not limited to patients, caregivers, and healthcare professionals.

### HOW ARE APLS USED?

APLS can help people better understand the research data in presentations at scientific congresses.

### WHAT INFORMATION DO APLS INCLUDE?

APLS summarize the original content of a scientific abstract. They describe the main aims and findings of a research study in an easy-to-understand format by following health literacy best practices.

### WHY DOES PFIZER DEVELOP APLS?

Research findings often use terms that can be too complex for many non-scientists to understand. APLS provide recent research results in a clear way for non-scientists.



## American Urological Association (AUA) Annual Meeting

Chicago, IL & Online | April 28-May 1, 2023

### PFIZER ABSTRACT PLAIN LANGUAGE SUMMARIES AND ACCOMPANYING SCIENTIFIC PRESENTATIONS AT AUA 2023

Presentations will go live on the dates marked below.

## Bladder Cancer

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy

Live Friday, April 28

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →



## Prostate Cancer

Diabetes, hypertension, and hyperlipidemia in patients with prostate cancer may predict risk of cardiovascular events after initiating ADT

Live Friday, April 28

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Preferences for key attributes of clinically available androgen deprivation therapies among men with prostate cancer

Live Friday, April 28

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Examining testosterone recovery in androgen deprivation therapy for prostate cancer

Live Saturday, April 29

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Real world characterization of patients receiving relugolix or androgen deprivation therapy injections in combination with oral anti-androgens in 2021 (The REAL ADT ORAL Study): Analysis from a US EMR Database

Live Saturday, April 29

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Real-world outcomes among men with nonmetastatic castration-sensitive biochemical recurrence after definitive therapy with short PSA doubling time receiving early secondary treatment

Live Saturday, April 29

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

EMBARC: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer

Live Saturday, April 29

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Treatment pattern and health-related quality of life (HRQoL) of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US)

Live Saturday, April 29

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

